- Xebra Brands has officially been granted its first product authorization to import, launch and sell legal CBD products in Mexico
- This is its first federal authorization for its 250mg Tangerine Flavour CBD Tincture
- The authorization was granted to Xebra Brands’ subsidiary Elements Biosciences S.A. de C.V. by Mexican regulatory authorities
- Shares of Xebra Brands are up 28.57 per cent to C$0.045 as of 9:48 am ET
Xebra Brands (CSE:XBRA) has officially received its first federal approval from Mexico for legal CBD products.
In a news release, the Vancouver-based company stated it has locked in approval from Mexican regulatory authorities for its 250mg Tangerine Flavour CBD Tincture through its subsidiary, Elements Bioscience S.A. de C.V.
“This milestone represents a significant step forward in our mission to make high-quality legal CBD products accessible to consumers,” Rodrigo Gallardo, interim CEO of Xebra Brands, said in a statement. “We are grateful for the support of regulatory authorities in Mexico and look forward to bringing our premium CBD tincture to customers across the country.”
The launch of the company’s CBD tincture in Mexico represents opportunities for customers seeking natural wellness solutions in Mexico, particularly CBD that continues to gain popularity for its therapeutic benefits.
The company’s Tangerine Flavour CBD includes premium CBD extract and premium tangerine flavouring.
Thanks to the authorization of Xebra Brands’ Tangerine Flavour CBD Tincture in Mexico, this makes the company’s first import authorization that will run in line with its domestically produced Mexican products.
Xebra Brands is an international cannabis company focused on the development and sale of cannabis and CBD products in Mexico.
Shares of Xebra Brands are up 28.57 per cent to C$0.045 as of 9:48 am ET.
Join the discussion: Find out what everybody’s saying about this stock on the Xebra Brands Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.